Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: estatemakr who wrote (359)	11/2/2007 5:17:00 PM
From: Keith Feral	Read Replies (1) \| Respond to of 418

The one thing that REALLY pisses me off is that Adventrx only enrolled 80 people for the phase 3. How was it that Levine planned to finish enrollment by the end of next year? Based on his positive comments, I would have thought Adventrx had enrolled a much higher number of people. At least the company has finally decided to get real and focus all of their efforts on Cofactor to opening the data base and selling the product to big pharma. They can sell the product to big pharma if they have good data from the phase 3 to support combination approach with Avastin, even if they have to start the phase 3 from square 1. In a strange way, today was the final day of the phase 3 testing for Cofactor even though the results won't be statistical. If they are meaningful, they can sell the product. If they aren't meaningful, they saved a shit load of money to use for other products. Even though this accelerates the end game scenario for Cofactor, it's the cheapest way to look at the data and sell the product to someone that can afford the full buildout of Cofactor trials.